# US 2018/0023143 A9 · Monitoring health and disease status using clonotype profiles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023143 A9
- Document ID: US20180023143A9
- Status: Published application
- Kind: A9
- Application number: 15/061,750
- Filed: 2016-03-04
- Published: 2018-01-25
- Earliest claimed: 2008-11-07
- Assignees: Adaptive Biotechnologies Corporation
- Applicants: Adaptive Biotechnologies Corp.
- Inventors: Malek FAHAM; Thomas Willis
- Web page: https://patentgrep.com/patent/US20180023143A9

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.

## Claims

### Claim at position 1

1-74. (canceled)

### Claim 75

A method for determining a relative quantity of tumor-infiltrating lymphocytes in a solid tumor, comprising:
(a) amplifying by PCR at least 100,000 rearranged TCR or Ig CDR3-encoding regions present in a sample comprising solid tumor tissue using a plurality of V-segment oligonucleotide primers and a plurality of J-segment oligonucleotide primers to produce a plurality of rearranged DNA amplicons;
(b) amplifying by PCR a control sequence present in said sample using a pair of control sequence primers, wherein said control sequence primers are capable of amplifying a control sequence that is present in all cells in said sample;
(c) quantifying a number of adaptive immune receptor sequence reads in said sample generated from high-throughput sequencing (HTS) of said plurality of rearranged DNA amplicons;
(d) quantifying a number of control sequence reads in said sample using said amplified control sequence; and
(e) comparing said number of adaptive immune receptor sequence reads and said number of control sequence reads to estimate a relative quantity of tumor-infiltrating lymphocytes in said solid tumor.

### Claim 76 (depends on 75)

The method of claim 75, further comprising quantifying a number of unique sequence reads generated from said HTS, wherein each unique sequence read comprises a sequence distinct from the other sequence reads.

### Claim 77 (depends on 75)

The method of claim 75, wherein said number of control sequence reads represents a total number of diploid genomes in said sample.

### Claim 78 (depends on 77)

The method of claim 77, wherein said comparing comprises dividing said number of control sequence reads in half and determining a ratio between said number of adaptive immune receptor sequence reads and half of said number of control sequence reads.

### Claim 79 (depends on 75)

The method of claim 75, wherein said comparing comprises estimating a total number of adaptive immune cells in said sample by dividing said number of adaptive immune receptor sequence reads by a numerical factor.

### Claim 80 (depends on 75)

The method of claim 75, wherein said plurality of rearranged DNA amplicons comprises at least 106DNA molecules.

### Claim 81 (depends on 75)

The method of claim 75, wherein said plurality of rearranged DNA amplicons comprises at least 105DNA molecules.

### Claim 82 (depends on 75)

The method of claim 75, wherein each V-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR or Ig V-encoding gene segment, and wherein said V-segment oligonucleotide primers specifically hybridize to at least 100,000 functional TCR or Ig V-encoding gene segments that are present in said sample.

### Claim 83 (depends on 75)

The method of claim 75, wherein each J-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR or Ig J-encoding gene segment, and wherein said J-segment oligonucleotide primers specifically hybridize to at least 100,000 functional TCR or Ig J-encoding gene segments that are present in said test sample.

### Claim 84 (depends on 75)

The method of claim 75, wherein each amplified rearranged TCR or Ig CDR3-encoding region is greater than 25 nucleotides in length.

### Claim 85 (depends on 75)

The method of claim 75, wherein each of said rearranged TCR or Ig CDR3-encoding regions encode a T cell receptor (TCR) V-region polypeptide or an immunoglobulin (Ig) V-region polypeptide comprising a V gene recombination signal sequence (RSS) and a T cell receptor (TCR) J-region polypeptide or an immunoglobulin (Ig) J-region polypeptide comprising a J gene RSS, and wherein each rearranged DNA amplicon comprises (i) at least 30, 40, 50 or 60 contiguous nucleotides of a sense strand of a TCR or Ig V-encoding gene segment, said at least 30, 40, 50 or 60 contiguous nucleotides being situated 5′ to said V gene RSS and (ii) at least 30, 40, 50 or 60 contiguous nucleotides of a sense strand of a TCR or Ig J-encoding gene segment, said at least 30, 40, 50 or 60 contiguous nucleotides being situated 3′ to said J gene RSS.

### Claim 86 (depends on 75)

The method of claim 75, wherein said tumor-infiltrating lymphocytes are T cells or B cells.

### Claim 87 (depends on 75)

The method of claim 75, wherein said rearranged TCR or Ig CDR3-encoding regions are selected from the group consisting of rearranged TCRα CDR3-encoding regions, TCRβ CDR3-encoding regions, TCRγ CDR3-encoding regions, TCRδ CDR3-encoding regions, IgH CDR3-encoding regions, Igκ CDR3-encoding regions, and Igλ CDR3-encoding regions.

### Claim 88

A method for quantifying a relative representation of tumor infiltrating T cells in a solid tissue tumor sample, comprising:
obtaining DNA templates from said solid tissue tumor sample;
amplifying rearranged T cell receptor DNA molecules utilizing a plurality of V-segment oligonucleotide primers and a plurality of J-segment oligonucleotide primers in a single multiplex PCR from said DNA templates to produce a multiplicity of amplified rearranged DNA molecules;
sequencing said multiplicity of amplified rearranged DNA molecules by high-throughput sequencing (HTS) to produce rearranged T cell receptor sequence reads;
determining a number of rearranged T cell receptor DNA molecules from said rearranged T cell receptor sequence reads, wherein said number of T cell receptor DNA molecules is proportional to a number of T cells in said sample;
determining a number of diploid genomes in the sample, wherein said number of diploid genomes represents a number of total cells in the sample; and
quantifying a ratio of the relative representation of tumor infiltrating T cells in said sample by comparing said number of T cells by said number of total cells in the sample.

### Claim 89 (depends on 88)

The method of claim 88, wherein each V-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR V-encoding gene segment, and wherein said V-segment oligonucleotide primers specifically hybridize to at least 100,000 functional TCR V-encoding gene segments that are present in said sample.

### Claim 90 (depends on 88)

The method of claim 88, wherein each J-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR J-encoding gene segment, and wherein said J-segment oligonucleotide primers specifically hybridize to at least 100,000 functional TCR J-encoding gene segments that are present in said test sample.

### Claim 91 (depends on 88)

The method of claim 88, wherein each of said rearranged TCR encodes a T cell receptor (TCR) V-region polypeptide comprising a V gene recombination signal sequence (RSS) and a T cell receptor (TCR) J-region polypeptide comprising a J gene RSS, and wherein each rearranged DNA molecule comprises (i) at least 30, 40, 50 or 60 contiguous nucleotides of a sense strand of a TCR V-encoding gene segment, said at least 30, 40, 50 or 60 contiguous nucleotides being situated 5′ to said V gene RSS and (ii) at least 30, 40, 50 or 60 contiguous nucleotides of a sense strand of a TCR J-encoding gene segment, said at least 30, 40, 50 or 60 contiguous nucleotides being situated 3′ to said J gene RSS.

### Claim 92 (depends on 88)

The method of claim 88, wherein said number of diploid genomes in said sample is determined by contacting said sample with a pair of control sequence primers and by amplifying a control sequence from said DNA templates, wherein said control sequence primers are capable of amplifying a control sequence present in all cells in said sample.

### Claim 93 (depends on 88)

The method of claim 88, further comprising quantifying a number of unique sequence reads generated from said HTS, wherein each unique sequence read comprises a sequence distinct from the other sequence reads.

### Claim 94 (depends on 88)

The method of claim 88, wherein said comparing comprises dividing said number of T cells by a numerical factor.

### Claim 95 (depends on 88)

The method of claim 88, wherein said rearranged DNA molecules are selected from the group consisting of rearranged TCRα CDR3-encoding regions, TCRβ CDR3-encoding regions, TCRγ CDR3-encoding regions, and TCRδ CDR3-encoding regions.

### Claim 96 (depends on 75)

The method of claim 75, wherein the amplifying steps of (a) and (b) are performed in the same PCR reaction.

### Claim 97 (depends on 75)

The method of claim 75, wherein the amplifying steps of (a) and (b) are performed in separate PCR reactions.
